Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | MMP15 | P51511 | 1/20 | 0.45 |
| ▸ | MMP16 | P51512 | 1/20 | 0.45 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1978446 | 0.93 | ALDH1A1 (0.50) | ALDH1A1KDM4EPOLBNPC1RAB9A | |
| SCHEMBL294854 | 0.77 | USP5 (0.62) | ALDH1A1KDM4EPOLBNPC1RAB9A | |
| SCHEMBL14243695 | 0.76 | PTGDR2 (0.52) | ALDH1A1KDM4EPOLBNPC1RAB9A | |
| SCHEMBL1978439 | 0.75 | DRD3 (0.44) | NPC1 | |
| SCHEMBL3235054 | 0.73 | PKM (0.57) | ALDH1A1KDM4EPOLBNPC1RAB9A | |
| SCHEMBL4516709 | 0.73 | PKM (0.57) | ALDH1A1KDM4EPOLBNPC1RAB9A | |
| SCHEMBL3235046 | 0.73 | PKM (0.57) | ALDH1A1KDM4EPOLBNPC1RAB9A | |
| SCHEMBL493725 | 0.72 | PKM (0.61) | ALDH1A1KDM4EPOLBNPC1RAB9A | |
| SCHEMBL1980009 | 0.72 | ALDH1A1 (0.46) | ALDH1A1POLBTSHRPKMMAPT | |
| SCHEMBL1978853 | 0.72 | HTR1A (0.39) | EBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509945-B1 | 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RES & DEV (FR) | 2014-03-05 | — | — | EP | claimed |
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-12-20 | — | — | US | claimed |
| EP-2509945-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | Galderma Research & Development (FR) | 2012-10-17 | — | — | EP | claimed |
| WO-2011070080-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-16 | — | — | WO | claimed |
| EP-2509945-B1 | 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RES & DEV (FR) | 2014-03-05 | — | — | EP | disclosed |
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-12-20 | — | — | US | disclosed |
| EP-2509945-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | Galderma Research & Development (FR) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011070080-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | TYR, DDT, TH | ALDH1A1 20/4885KDM4E 787/4885POLB 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.